| 2026-02-26 |
详情>>
内部人交易：
Francis Chris共交易4笔
|
| 2026-02-26 |
详情>>
股本变动：
变动后总股本18825.50万股
|
| 2026-02-26 |
详情>>
业绩披露：
2025年年报每股收益-1.21美元,归母净利润-2.04亿美元,同比去年增长-110.68%
|
| 2026-02-26 |
财报披露：
美东时间 2026-02-26 盘前发布财报
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.92美元,归母净利润-1.51亿美元,同比去年增长-19.75%
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-0.6美元,归母净利润-9734.7万美元,同比去年增长-50.97%
|
| 2025-06-23 |
股东大会：
将于2025-08-05召开股东大会
会议内容 ▼▲
- 1.To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2026 Annual General Meeting of Shareholders;
3.To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, to increase the total number of ordinary shares available for issuance under the 2021 Equity Incentive Plan, as amended, by 8,000,000 ordinary shares in the manner and on the basis as set forth under “Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended” in the attached proxy statement;
5.Pursuant to the provisions of Section 161 of the Companies Act 1967 of Singapore (the “Singapore Companies Act”), and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
6.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:
7.To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers:
8.To transact such other business as may properly come before the 2025 AGM and all adjournments or postponements thereof.
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.29美元,归母净利润-4687.8万美元,同比去年增长-48.55%
|
| 2025-03-04 |
详情>>
业绩披露：
2024年年报每股收益-0.7美元,归母净利润-9700.8万美元,同比去年增长-68.67%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.97美元,归母净利润-1.26亿美元,同比去年增长-206.04%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.5美元,归母净利润-6448.1万美元,同比去年增长-32.93%
|
| 2024-06-21 |
股东大会：
将于2024-08-06召开股东大会
会议内容 ▼▲
- 1.(a)To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors;(b)To elect Mark H.N. Corrigan, M.D. to serve on the Board of Directors;(c)To elect Christian Henry to serve on the Board of Directors;(d)To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;(e)To elect Adrian Rawcliffe to serve on the Board of Directors;(f)To elect Ken Takanashi to serve on the Board of Directors;(g)To elect Aik Na Tan to serve on the Board of Directors;(h)To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;(i)To elect Heidi L. Wagner, J.D. to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2024, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2025 Annual General Meeting of Shareholders;
3.To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, to increase the total number of ordinary shares available for issuance under the 2021 Equity Incentive Plan, as amended, by 5,000,000 ordinary shares in the manner and on the basis as set forth under “Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended” in the attached proxy statement;
5.Pursuant to the provisions of Section 161 of the Companies Act 1967 of Singapore (the “Singapore Companies Act”), and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors.
6.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:“RESOLVED, on a non-binding, advisory basis only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the U.S. Securities and Exchange Commission, including the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.”
7.To transact such other business as may properly come before the 2024 AGM and all adjournments or postponements thereof.
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.24美元,归母净利润-3155.8万美元,同比去年增长-15.15%
|
| 2024-03-06 |
详情>>
业绩披露：
2023年年报每股收益-0.54美元,归母净利润-5751.3万美元,同比去年增长64.46%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.39美元,归母净利润-4125.7万美元,同比去年增长65.07%
|
| 2023-06-26 |
股东大会：
将于2023-08-01召开股东大会
会议内容 ▼▲
- 1.(a)To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors;(b)To elect Mark H.N. Corrigan, M.D. to serve on the Board of Directors;(c)To elect Christian Henry to serve on the Board of Directors;(d)To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;(e)To elect Adrian Rawcliffe to serve on the Board of Directors;(f)To elect Adrian Rawcliffe to serve on the Board of Directors;(g)To elect Aik Na Tan to serve on the Board of Directors;(h)To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;(i)To elect Heidi L. Wagner, J.D. to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2023, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2024 Annual General Meeting of Shareholders;
3.To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.To approve a proposed amendment to the Company’s 2021 Equity Incentive Plan, as amended, to increase the total number of ordinary shares available for issuance under the 2021 Equity Incentive Plan, as amended, by 6,500,000 ordinary shares in the manner and on the basis as set forth under “Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended” in the attached proxy statement;
5.To approve a proposed amendment to the Company’s 2019 Employee Share Purchase Plan to increase the total number of ordinary shares available for issuance under the 2019 Employee Share Purchase Plan by 2,000,000 ordinary shares in the manner and on the basis as set forth under “Proposal 5: Approval of an Amendment to the 2019 Employee Share Purchase Plan” in the attached proxy statement;
6.Pursuant to the provisions of Section 161 of the Companies Act 1967 of Singapore (the “Singapore Companies Act”), and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:(a)to:(i)allot and issue ordinary shares in our capital;(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares), at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2024 Annual General Meeting of Shareholders or the expiration of the period within which our 2024 Annual General Meeting of Shareholders is required by law to be held;
7.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:“RESOLVED, on a non-binding, advisory basis only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.”This non-binding advisory resolution is being proposed to shareholders as required pursuant to the requirements of Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shareholders’ vote on this proposal is solely advisory and non-binding in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors;
8.To transact such other business as may properly come before the 2023 AGM and all adjournments or postponements thereof.
|
| 2023-05-23 |
复牌提示：
2023-05-23 07:25:11 停牌，复牌日期 2023-05-23 08:00:00
|
| 2022-06-29 |
股东大会：
将于2022-08-09召开股东大会
会议内容 ▼▲
- 1.(A)To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors;(b)To elect Mark H.N. Corrigan, M.D. to serve on the Board of Directors;(c)To elect Christian Henry to serve on the Board of Directors;(d)To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;(e)To elect Adrian Rawcliffe to serve on the Board of Directors;(f)To elect Ken Takanashi to serve on the Board of Directors;(g)To elect Aik Na Tan to serve on the Board of Directors;(h)To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;(i)To elect Heidi L. Wagner, J.D. to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2022, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2023 Annual General Meeting of Shareholders;
3.To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.To approve a proposed amendment to the Company’s 2021 Equity Incentive Plan to increase the total number of ordinary shares available for issuance under the 2021 Equity Incentive Plan by 6,000,000 ordinary shares in the manner and on the basis as set forth under “Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan” in the attached proxy statement;
5.Pursuant to the provisions of Section 161 of the Companies Act 1967 of Singapore (the “Singapore Companies Act”), and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:(a)to:(i)allot and issue ordinary shares in our capital;(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2023 Annual General Meeting of Shareholders or the expiration of the period within which our 2023 Annual General Meeting of Shareholders is required by law to be held;
6.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:“RESOLVED, on a non-binding, advisory basis only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.”This non-binding advisory resolution is being proposed to shareholders as required pursuant to the requirements of Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shareholders’ vote on this proposal is solely advisory and non-binding in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors;
7.To transact such other business as may properly come before the 2022 AGM and all adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-28 |
股东大会：
将于2021-08-10召开股东大会
会议内容 ▼▲
- 1.To elect nine Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2021, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2022 Annual General Meeting of Shareholders;
3.To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees (including payment in arrears to the Research and Development Committee for service for the period of January 1, 2021 through the date of the 2021 AGM and payments relating to withholding taxes to be paid to the U.S. Internal Revenue Service on behalf of one of our ex-U.S. Directors), in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.To approve the Company’s 2021 Equity Incentive Plan in the manner and on the basis as set forth under “Proposal 4: Approval of the 2021 Equity Incentive Plan” in the attached proxy statement, and for our Board of Directors and/or a committee of our Board of Directors, to be authorized to (a) grant awards in accordance with the provisions of the 2021 Equity Incentive Plan; and (b) allot and issue from time to time such number of ordinary shares as may be required to be issued pursuant to the grant of awards under the 2021 Equity Incentive Plan;
5.Pursuant to the provisions of Section 161 of the Singapore Companies Act (the “Singapore Companies Act”), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
(a)to:
(i)allot and issue ordinary shares in our capital; and/or
(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),
at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;
(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2022 Annual General Meeting of Shareholders or the expiration of the period within which our 2022 Annual General Meeting of Shareholders is required by law to be held;
6.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:“RESOLVED, on a non-binding, advisory basis only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.”This non-binding advisory resolution is being proposed to shareholders as required pursuant to the requirements of Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shareholders’ vote on this proposal is solely advisory and non-binding in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors;
7.To transact such other business as may properly come before the 2021 AGM and all adjournments or postponements thereof.
|
| 2020-06-26 |
股东大会：
将于2020-08-12召开股东大会
会议内容 ▼▲
- 1.(a)To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors;
(b)To elect Mark H.N. Corrigan, M.D. to serve on the Board of Directors;
(c)To elect Christian Henry to serve on the Board of Directors;
(d)To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;
(e)To elect Amy Pott to serve on the Board of Directors;
(f)To elect Adrian Rawcliffe to serve on the Board of Directors;
(g)To elect Ken Takanashi to serve on the Board of Directors;
(h)To elect Aik Na Tan to serve on the Board of Directors;
(i)To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;
(j)To elect Heidi L. Wagner, J.D. to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2020, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2021 Annual General Meeting of Shareholders;
3.To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.Pursuant to the provisions of Section 161 of the Singapore Companies Act (the “Singapore Companies Act”), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
(a)to:
(i)allot and issue ordinary shares in our capital; and/or
(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),
at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;
(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2021 Annual General Meeting of Shareholders or the expiration of the period within which our 2021 Annual General Meeting of Shareholders is required by law to be held;
5.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:“RESOLVED, on a non-binding, advisory basis only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.”This non-binding advisory resolution is being proposed to shareholders as required pursuant to the requirements of Section 14A of the Securities Exchange Act of 1934, as amended, or the “Exchange Act.” The shareholders’ vote on this proposal is solely advisory and non-binding in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors;
6.To transact such other business as may properly come before the 2020 AGM and all adjournments or postponements thereof.
|
| 2019-06-26 |
股东大会：
将于2019-08-08召开股东大会
会议内容 ▼▲
- 1.(a)To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors;
(b)To elect Christian Henry to serve on the Board of Directors;
(c)To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;
(d)To elect Koji Miura to serve on the Board of Directors;
(e)To elect Adrian Rawcliffe to serve on the Board of Directors;
(f)To elect Ken Takanashi to serve on the Board of Directors;
(g)To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2019, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2020 Annual General Meeting of Shareholders;
3.To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.Pursuant to the provisions of Section 161 of the Singapore Companies Act (the “Singapore Companies Act”), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
(a) to:
(i)allot and issue ordinary shares in our capital; and/or
(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),
at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;
(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2020 Annual General Meeting of Shareholders or the expiration of the period within which our 2020 Annual General Meeting of Shareholders is required by law to be held;
5.To approve the Company’s 2019 Employee Share Purchase Plan, and for our Board of Directors to be authorized to: (a) grant options to purchase ordinary shares in accordance with the provisions of the 2019 Employee Share Purchase Plan; and (b) allot and issue from time to time such number of fully paid-up ordinary shares as may be required to be issued pursuant to the exercise of options under the 2019 Employee Share Purchase Plan;
6.To approve, on a non-binding, advisory basis only, the compensation of our named executive officers:
“RESOLVED, on a non-binding, advisory basis only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.”
This non-binding advisory resolution is being proposed to shareholders as required pursuant to the requirements of Section 14A of the Securities Exchange Act of 1934, as amended, or the “Exchange Act.” The shareholders’ vote on this proposal is solely advisory and non-binding in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors;
7.
To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers:
“RESOLVED, on a non-binding, advisory basis only, that the shareholders recommend that a non-binding, advisory vote to approve the compensation paid to the named executive officers of the Company be put to shareholders for their consideration with one of the following three frequencies:
(a)every year;
(b)every two years;
(c)every three years.”
This non-binding advisory resolution is being proposed to shareholders as required pursuant to the requirements of Section 14A of the Exchange Act. The shareholders’ vote on this proposal is solely advisory and non-binding in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors;
8.To transact such other business as may properly come before the 2019 AGM and all adjournments or postponements thereof.
|
| 2018-06-28 |
股东大会：
将于2018-08-07召开股东大会
会议内容 ▼▲
- 1.(a)To elect Paul B. Bolno, M.D. to serve on the Board of b) To elect Christian Henry to serve on the Board of Directors;
(c)To elect Peter Kolchinsky, Ph.D. to serve on the Board of (d) To elect Koji Miura to serve on the Board of Directors;
(e)To elect Adrian Rawcliffe to serve on the Board of Directors;
(f)To elect Ken Takanashi to serve on the Board of Directors;
(g)To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;
2.To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2018, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2019 Annual General Meeting of Shareholders;
3.To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4.Pursuant to the provisions of Section 161 of the Singapore Companies Act (the “Singapore Companies Act”), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
(a) to:
(i) allot and issue ordinary shares in our capital; and/or
(ii) make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),
at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;
(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,
and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2019 Annual General Meeting of Shareholders or the expiration of the period within which our 2019 Annual General Meeting of Shareholders is required by law to be held;
5.To transact such other business as may properly come before the 2018 AGM and all adjournments or postponements thereof.
|
| 2017-07-06 |
股东大会：
将于2017-08-10召开股东大会
会议内容 ▼▲
- 1. (a) To elect Paul B. Bolno, M.D. to serve on the Board of Directors;
(b) To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;
(c) To elect Christian Henry to serve on the Board of Directors;
(d) To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;
(e) To elect Koji Miura to serve on the Board of Directors;
(f) To elect Adrian Rawcliffe to serve on the Board of Directors;
(g) To elect Ken Takanashi to serve on the Board of Directors;
2. To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2017, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2018 Annual General Meeting of Shareholders;
3. To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4. To approve proposed amendments to our WAVE Life Sciences Ltd. 2014 Equity Incentive Plan to increase the total number of shares available for the grant of awards; to increase the U.S. Internal Revenue Code Section 162(m) limit for the grant of equity awards and to add the material terms of performance goals to preserve our ability to receive corporate income tax deductions that may become available pursuant to Section 162(m), as set forth under “Proposal 4: Approval of Amendments to 2014 Equity Incentive Plan”;
5.Pursuant to the provisions of Section 161 of the Singapore Companies Act (the “Singapore Companies Act”), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
(a)to:
(i)allot and issue ordinary shares in our capital;
(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),
at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution;
(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2018 Annual General Meeting of Shareholders or the expiration of the period within which our 2018 Annual General Meeting of Shareholders is required by law to be held;
6.To transact such other business as may properly come before the 2017 AGM and all adjournments or postponements thereof.
|
| 2016-07-15 |
股东大会：
将于2016-08-18召开股东大会
会议内容 ▼▲
- 1. (a) To elect Paul B. Bolno, M.D. to serve on the Board of Directors;
(b) To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors;
(c) To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors;
(d) To elect Koji Miura to serve on the Board of Directors;
(e) To elect Ken Takanashi to serve on the Board of Directors;
(f) To elect Masaharu Tanaka to serve on the Board of Directors;
(g) To elect Takeshi Wada, Ph.D. to serve on the Board of Directors;
2. To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2016 and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of our 2017 Annual General Meeting of Shareholders;
3. To approve the Company’s payment of cash and equity-based compensation to non-employee directors for service on the Board and its committees, in the manner and on the basis as set forth under “Proposal 3: Non-Employee Directors’ Compensation” in the attached proxy statement;
4. Pursuant to the provisions of Section 161 of the Singapore Companies Act (the “Singapore Companies Act”), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors:
(a)to:
(i)allot and issue ordinary shares in our capital
(ii)make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into ordinary shares),
at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution
(b)to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance,
and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2017 Annual General Meeting of Shareholders or the expiration of the period within which our 2017 Annual General Meeting of Shareholders is required by law to be held
5. To transact such other business as may properly come before the 2016 AGM and all adjournments or postponements thereof.
|